Cargando…
Toward the development of a protein-based group B Streptococcus vaccine
Clinical trials of protein-based vaccines to prevent Group B streptococcal infections are underway. In this issue of Cell Reports Medicine, Pawlowski et al.(1) provide an extensive characterization of the immune response generated by the recently tested GBS-NN vaccine.
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Elsevier
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8861943/ https://www.ncbi.nlm.nih.gov/pubmed/35243427 http://dx.doi.org/10.1016/j.xcrm.2022.100536 |